ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

Company Overview

ASLAN Pharmaceuticals Ltd is a clinical‐stage biotechnology company focused on the discovery and development of novel immunology and oncology therapies. The company leverages proprietary antibody and small‐molecule platforms to address critical biological targets involved in tumor immune evasion and inflammatory disease pathways. ASLAN’s R&D approach combines modern protein engineering, antibody-drug conjugates and precision small‐molecule design to generate next‐generation therapeutics.

The company’s lead clinical programs include ASLAN003, an orally available allosteric IRAK4 inhibitor designed to modulate innate immune signaling in severe inflammatory diseases, and ASLAN004, a high-affinity nanobody targeting the CD39 ectonucleotidase to reinvigorate anti-tumor immune responses. In addition to these assets, ASLAN is advancing a diversified preclinical pipeline that features antibody-drug conjugates for solid tumors and multi-specific antibody formats aimed at difficult-to-treat cancers.

Founded in Singapore in 2015, ASLAN has established operations across Asia, Australia and the United States to support global clinical development. The company completed its initial public offering on the Nasdaq in 2020 and maintains a management team with extensive leadership experience in biopharmaceutical research, regulatory affairs and commercial strategy. ASLAN continues to pursue strategic partnerships and clinical collaborations to accelerate its programs toward regulatory milestones and potential market authorization.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.48 to $25.44
• Volume: N/A
• Average Volume: 122,322 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/11/2023
• Today: 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASLN
• CIK: 1722926
• Web: www.aslanpharma.com
• Phone: 65-6817-9598
• Fax: 65-6225-2419
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.22 million
• Net Margins: N/A
• Pretax Margin: -290.83%
• Return on Equity: -8,454.87%
• Return on Assets: -121.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $12 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 2,044,000
• Free Float: 1,948,000
• Market Cap: $1.23 million
• Optionable: No Data
• Beta: 1.40